1. Home
  2. XPL vs CRDF Comparison

XPL vs CRDF Comparison

Compare XPL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solitario Resources Corp.

XPL

Solitario Resources Corp.

HOLD

Current Price

$0.66

Market Cap

75.7M

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.33

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPL
CRDF
Founded
1984
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.7M
86.8M
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
XPL
CRDF
Price
$0.66
$1.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$1.20
$9.63
AVG Volume (30 Days)
223.5K
862.6K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
42.86
27.37
EPS
N/A
N/A
Revenue
N/A
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$0.53
$0.76
52 Week High
$0.98
$3.31

Technical Indicators

Market Signals
Indicator
XPL
CRDF
Relative Strength Index (RSI) 42.29 69.19
Support Level $0.60 $1.35
Resistance Level $0.80 $1.47
Average True Range (ATR) 0.05 0.09
MACD 0.00 0.03
Stochastic Oscillator 57.47 71.74

Price Performance

Historical Comparison
XPL
CRDF

About XPL Solitario Resources Corp.

Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: